NEPHROBLASTOMA TREATMENT MARKET ANALYSIS

Nephroblastoma Treatment Market, by Type (Favorable histology and Anaplastic histology), by Drug Type (Dactinomycin (Cosmegen), Doxorubicin (Adriamycin), Vincristine (Vincasar PFS, Oncovin), Cyclophosphamide (Cytoxan, Neosar), Etoposide (Toposar, VePesid), Irinotecan (Camptosar), and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Aug 2022
Code : CMI5192
Pages :156
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

High treatment cost of nephroblastoma

Global Nephroblastoma Treatment Market: Restraint

The major factor that hinders growth of the global nephroblastoma treatment market includes high treatment cost of nephroblastoma. For instance, according to an article published by the American Society of Clinical Oncology, in November 2018, the cost for a full course of treatment and follow-up was determined to be between US$ 1,490 and US$ 2,093 for a patient with nephroblastoma according to the study at the Butaro Cancer Center of Excellence (BCCOE), located at the Butaro District Hospital in rural northern Rwanda, Central Africa.

Nephroblastoma Treatment Market Report Snapshots